Dynamic Advisors Solutions LLC lessened its holdings in Edwards Lifesciences Corp (NYSE:EW) by 6.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,791 shares of the medical research company’s stock after selling 500 shares during the period. Dynamic Advisors Solutions LLC’s holdings in Edwards Lifesciences were worth $765,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also made changes to their positions in the company. BlackRock Inc. lifted its stake in Edwards Lifesciences by 2.2% during the 4th quarter. BlackRock Inc. now owns 15,410,737 shares of the medical research company’s stock worth $1,736,943,000 after acquiring an additional 331,896 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Edwards Lifesciences by 45.7% during the 4th quarter. Bank of New York Mellon Corp now owns 7,580,924 shares of the medical research company’s stock worth $854,444,000 after acquiring an additional 2,377,444 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Edwards Lifesciences by 20.2% during the 3rd quarter. Wells Fargo & Company MN now owns 2,548,282 shares of the medical research company’s stock worth $278,553,000 after acquiring an additional 429,022 shares in the last quarter. American Century Companies Inc. lifted its stake in Edwards Lifesciences by 7.0% during the 3rd quarter. American Century Companies Inc. now owns 2,224,010 shares of the medical research company’s stock worth $243,107,000 after acquiring an additional 144,701 shares in the last quarter. Finally, Artisan Partners Limited Partnership increased its holdings in Edwards Lifesciences by 12.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 1,432,428 shares of the medical research company’s stock worth $156,579,000 after purchasing an additional 153,896 shares during the period. 81.23% of the stock is currently owned by institutional investors and hedge funds.
Edwards Lifesciences Corp (NYSE EW) opened at $133.82 on Tuesday. The stock has a market capitalization of $28,105.37, a P/E ratio of 35.22, a P/E/G ratio of 1.98 and a beta of 0.63. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.41 and a current ratio of 1.81. Edwards Lifesciences Corp has a 12 month low of $89.20 and a 12 month high of $138.48.
Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.91 by $0.03. The firm had revenue of $888.50 million for the quarter, compared to the consensus estimate of $868.45 million. Edwards Lifesciences had a return on equity of 27.69% and a net margin of 18.11%. The firm’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.75 EPS. analysts expect that Edwards Lifesciences Corp will post 4.49 earnings per share for the current fiscal year.
Edwards Lifesciences announced that its board has approved a stock repurchase plan on Thursday, December 7th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.
Several equities research analysts have weighed in on EW shares. Cowen set a $135.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a report on Sunday, December 10th. Evercore ISI started coverage on Edwards Lifesciences in a report on Wednesday, January 3rd. They set an “outperform” rating and a $140.00 price target on the stock. Barclays upgraded Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $125.00 to $135.00 in a report on Thursday, January 4th. Deutsche Bank dropped their price objective on Edwards Lifesciences from $122.00 to $115.00 and set a “hold” rating on the stock in a report on Thursday, October 26th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $137.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, November 29th. Three investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Edwards Lifesciences currently has a consensus rating of “Buy” and a consensus target price of $141.15.
In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,800 shares of the stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $126.69, for a total transaction of $4,155,432.00. Following the completion of the sale, the chief executive officer now directly owns 74,131 shares of the company’s stock, valued at approximately $9,391,656.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 3,750 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $127.54, for a total value of $478,275.00. Following the sale, the vice president now directly owns 19,608 shares of the company’s stock, valued at $2,500,804.32. The disclosure for this sale can be found here. Insiders have sold a total of 172,630 shares of company stock worth $20,648,221 in the last 90 days. 2.13% of the stock is currently owned by company insiders.
WARNING: This article was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/20/edwards-lifesciences-corp-ew-stake-lowered-by-dynamic-advisors-solutions-llc.html.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.